Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma at a ...
December 05 2017 - 7:00AM
Business Wire
Event and Live Webcast to be Held on December
10th at 8:15 PM ET in Atlanta
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and
developing drugs to improve the survival and quality of life of
cancer patients, will present clinical data from the Phase 3 DUO
study evaluating the efficacy and safety of duvelisib in patients
with relapsed or refractory chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL) at a Research and
Development reception at the American Society of Hematology (ASH)
2017 Annual Meeting. The event will take place on Sunday, December
10, 2017 in Atlanta.
The event, which follows the oral presentation of the DUO data
results at ASH, will feature a slide presentation and moderated
panel discussion with recognized experts in the treatment of
hematologic malignancies, including CLL/SLL, and a live Q&A
session. Speakers will include Ian Flinn, MD, PhD, Sarah Cannon
Research Institute, who will present results from the Phase 3 DUO
study, and Steven Horwitz, MD, Memorial Sloan Kettering Cancer
Center, who will provide an update on duvelisib for the treatment
of Peripheral T-Cell Lymphoma (PTCL). In addition, Lori Kunkel, MD,
Verastem Clinical and Scientific Advisory Board, and Steven Bloom,
Verastem Chief Strategy Officer, will participate in the discussion
panel and Q&A session, which will be moderated by Robert
Forrester, Verastem President and Chief Executive Officer.
The event will take place during the ASH 2017 Annual Meeting and
is open to analysts and institutional investors. Interested parties
can access a live webcast of the event beginning Sunday, December
10, 2017 at 8:15 p.m. ET on the "Presentations" page of the
company's website
http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-calendar.
A replay of the webcast will be archived on the company's website
for 90 days following the event. For more information or to RSVP,
please contact Maeve Conneighton at maeve@argotpartners.com.
Duvelisib is Verastem’s first in class oral dual inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma which is
currently being developed for the treatment of CLL/SLL, peripheral
T cell lymphoma (PTCL), and other hematologic malignancies.
About Duvelisib
Duvelisib is a first-in-class investigational, dual inhibitor of
phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, two enzymes
known to help support the growth and survival of malignant B-cells
and T-cells. PI3K signaling may lead to the proliferation of
malignant B-cells and is thought to play a role in the formation
and maintenance of the supportive tumor
microenvironment.1,2,3 Duvelisib is currently being evaluated
in late- and mid-stage extension trials, including DUO™, a
randomized, Phase 3 monotherapy study in patients with relapsed or
refractory chronic lymphocytic leukemia (CLL)/small lymphocytic
lymphoma (SLL),4 and DYNAMO™, a single-arm, Phase 2
monotherapy study in patients with refractory indolent non-Hodgkin
lymphoma (iNHL).5 Both DUO and DYNAMO achieved their primary
endpoints and Verastem intends to submit a New Drug
Application (NDA) requesting the full approval of duvelisib for the
treatment of patients with relapsed or refractory CLL/SLL, and
accelerated approval for the treatment of patients with relapsed or
refractory follicular lymphoma (FL). Duvelisib is also being
developed by Verastem for the treatment of peripheral
T-cell lymphoma (PTCL), and is being investigated in combination
with other agents through investigator-sponsored
studies.6 Information about duvelisib clinical trials can be
found on www.clinicaltrials.gov.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company
focused on discovering and developing drugs to improve outcomes for
patients with cancer. Verastem is currently developing duvelisib, a
dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully
met its primary endpoint in a Phase 2 study in iNHL and a Phase 3
clinical trial in patients with CLL/SLL. In addition, Verastem is
developing the FAK inhibitor defactinib, which is currently being
evaluated in three separate clinical collaborations in combination
with immunotherapeutic agents for the treatment of several
different cancer types, including pancreatic cancer, ovarian
cancer, non-small cell lung cancer, and mesothelioma. Verastem’s
product candidates seek to treat cancer by modulating the local
tumor microenvironment, enhancing anti-tumor immunity, and reducing
cancer stem cells. For more information, please visit
www.verastem.com.
References
1 Winkler et al. PI3K-delta and PI3K-gamma inhibition by IPI-145
abrogates immune responses and suppresses activity in autoimmune
and inflammatory disease models. Chem Biol 2013; 20:1-11.2 Reif et
al. Cutting Edge: Differential roles for phosphoinositide 3
kinases, p110-gamma and p110-delta, in lymphocyte chemotaxis and
homing. J Immunol 2004:173:2236-2240.3 Schmid et al. Receptor
tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell
PI3K, a single convergent point promoting tumor inflammation and
progression. Cancer Cell 2011;19:715-727.4 www.clinicaltrials.gov,
NCT020045225 www.clinicaltrials.gov, NCT018828036
www.clinicaltrials.gov, NCT02783625, NCT02158091
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171205005400/en/
Verastem, Inc.Brian Sullivan, 781-292-4214Director,
Corporate Developmentbsullivan@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024